tirzepatide weight loss trial results The SURMOUNT-MAINTAIN Phase 3b is testing if adults with obesity can maintain by continuing or reducing (vs placebo) after achieving on the highest dose. #Tirzepatide https://t.co/FHyoDXDEYv Success Stories of Tirzepatide &

The marketing also makes bold claims like "Lose 27 lbs in 60 Days" that feel overly promotional

Oral GLP-1 medications may be a reasonable option for: Patients early in their weight loss journey Patients with mild to moderate weight loss goals Patients who strongly prefer to avoid injections They may be less ideal for: Patients who have had bariatric surgery Patients needing significant weight loss Patients who have not responded to oral medications in the past The decision is not just about preference

Problems with social functioning (such as inability to eat with others)

Hryciw DH, Patten RK, Rodgers RJ, Proietto J, Hutchinson DS, McAinch AJ (2024) GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates

Some large employers may opt into more generous plans that include coverage for weight loss medications, while others stick to a more basic, cost-effective formulary that excludes them entirely